We assessed the efficacy of an inactivated hepatitis B vaccine in a placebo-controlled, randomized, double-blind trial in 1083 homosexual men known to be at high risk for hepatitis B virus infection. The vaccine was found to be safe and the incidence of side effects was low. Within two months, 77% of the vaccinated persons had high levels of antibody against the hepatitis B surface antigen. This rate increased to 96% after the booster dose and remained essentially unchanged for the duration of the trial. For the first 18 months of follow-up, hepatitis B or subclinical infection developed in only 1.4 to 3.4% of the vaccine recipients as compared with 18 to 27% of placebo recipients (P < 0.0001). The reduction of incidence in the vaccinees was as high as 92.3%; none of the vaccinees with a detectable immune response to the vaccine had clinical hepatitis B or asymptomatic antigenemia. A significant reduction of incidence was already seen within 75 days after randomization; this observation suggests that the vaccine may be efficacious even when given after exposure.
This article has been cited by other articles:
Sapru, A., Kulkarni, P. S., Bhave, S., Bavdekar, A., Naik, S. S., Pandit, A. N.
(2007). Immunogenicity and Reactogenicity of Two Recombinant Hepatitis B Vaccines in Small Infants: A Randomized, Double-Blind Comparative Study. J Trop Pediatr
53: 303-307
[Abstract][Full Text]
Aggarwal, R., Ranjan, P.
(2004). Preventing and treating hepatitis B infection. BMJ
329: 1080-1086
[Full Text]
Kong, Q., Richter, L., Yang, Y. F., Arntzen, C. J., Mason, H. S., Thanavala, Y.
(2001). Oral immunization with hepatitis B surface antigen expressed in transgenic plants. Proc. Natl. Acad. Sci. USA
10.1073/pnas.191617598v1
[Abstract][Full Text]
Mahoney, F. J.
(1999). Update on Diagnosis, Management, and Prevention of Hepatitis B Virus Infection. Clin. Microbiol. Rev.
12: 351-366
[Abstract][Full Text]
Lemon, S. M., Thomas, D. L.
(1997). Vaccines to Prevent Viral Hepatitis. NEJM
336: 196-204
[Full Text]
Krahn, M., Detsky, A. S.
(1993). Should Canada and the United States Universally Vaccinate Infants against Hepatitis B?: A Cost - Effectiveness Analysis. Med Decis Making
13: 4-20
[Abstract]
Hicks, R. A., Cullen, J. W., Jackson, M. A., Burry, V. F.
(1989). Hepatitis B Virus Vaccine: Cost-Benefit Analysis of its Use in a Children's Hospital. CLIN PEDIATR
28: 359-365
[Abstract]
Kuo, G, Choo, Q., Alter, H., Gitnick, G., Redeker, A., Purcell, R., Miyamura, T, Dienstag, J., Alter, M., Stevens, C., et, al.
(1989). An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science
244: 362-364
[Abstract]
Reese, C. E., Ockner, R. K.
(1989). Prevention of Hepatitis B in Surgeons and Their Patients. PERSPECT VASC SURG ENDOVASC THER
2: 138-147
Stoneburner, R., Des Jarlais, D., Benezra, D, Gorelkin, L, Sotheran, J., Friedman, SR, Schultz, S, Marmor, M, Mildvan, D, Maslansky, R
(1988). A larger spectrum of severe HIV-1--related disease in intravenous drug users in New York City. Science
242: 916-919
[Abstract]
Remafedi, G. J.
(1985). Adolescent Homosexuality: Issues for Pediatricians. CLIN PEDIATR
24: 481-485
[Abstract]
Kennedy, R., Melnick, J., Dreesman, G.
(1984). Antibody to hepatitis B virus induced by injecting antibodies to the idiotype. Science
223: 930-931
[Abstract]
Koplan, J. P., Kane, M. A.
(1982). Management of Needle-Stick Exposures. Med Decis Making
2: 129-131
Tiollais, P, Charnay, P, Vyas, G.
(1981). Biology of hepatitis B virus. Science
213: 406-411
[Abstract]
Kong, Q., Richter, L., Yang, Y. F., Arntzen, C. J., Mason, H. S., Thanavala, Y.
(2001). Oral immunization with hepatitis B surface antigen expressed in transgenic plants. Proc. Natl. Acad. Sci. USA
98: 11539-11544
[Abstract][Full Text]
